Comparative Pharmacology
Head-to-head clinical analysis: CHLOROPTIC S O P versus NITROFURANTOIN MONOHYDRATE MACROCRYSTALS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROPTIC S O P versus NITROFURANTOIN MONOHYDRATE MACROCRYSTALS.
CHLOROPTIC S.O.P. vs NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial cell wall synthesis, protein synthesis, and DNA/RNA synthesis. It is bacteriostatic at low concentrations and bactericidal at higher concentrations.
Apply 0.5-inch ribbon into the conjunctival sac(s) 1-2 times daily, or more frequently as directed.
100 mg orally twice daily for 5-7 days; for uncomplicated urinary tract infection.
None Documented
None Documented
Terminal half-life approximately 4-6 hours; clinical context: dosing every 4-6 hours for ocular infections
Terminal elimination half-life: 20-60 minutes (average ~30 min) in patients with normal renal function; prolonged in renal impairment (e.g., CrCl <60 mL/min).
Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%)
Renal excretion of unchanged drug accounts for approximately 40% of the dose; tubular reabsorption occurs. Biliary/fecal elimination is minimal (<5%).
Category C
Category D/X
Antibiotic
Antibiotic